A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is
- Find out if patients receiving Sorafenib will live longer
- Find out if Sorafenib has any effect on patient reported outcomes
- Find out if Sorafenib prevents the growth or shrinks liver tumors and / or their
metastases
- Determine the pharmacokinetics (PK) in patients with liver cancer